{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:57:56Z","timestamp":1789595876914,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","award":["R396-2022-301"],"award-info":[{"award-number":["R396-2022-301"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002918","name":"Copenhagen University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002918","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Migraine is a leading cause of disability worldwide, and triptans, the most widely used acute treatment, act through vasoconstriction and are contraindicated in patients with vascular disease. Rimegepant, a calcitonin gene-related peptide receptor antagonist, is proposed as a non-vasoconstrictive alternative, but its direct vascular effects during spontaneous migraine attacks have not been examined. This was a prospective, longitudinal study conducted at a single academic imaging centre between 12 January 2024 and 10 June 2025. Eighteen women aged 18\u201340 years with menstrually related migraine without aura were enrolled. Fifteen participants completed high-resolution 3\u2005T magnetic resonance angiography during a spontaneous migraine attack before, and at 30 and 60\u2005min after, administration of a single 75\u2005mg oral dose of rimegepant. The primary outcome was change in arterial circumference of the cerebral artery and meningeal artery. Circumference was measured in millimetre and compared using paired samples t-tests. No significant vasoconstriction was observed in either artery following rimegepant administration. Cerebral artery circumference remained stable (baseline 8.13 \u00b1 0.93\u2005mm; 30\u2005min 8.02 \u00b1 0.84\u2005mm, P = 0.404; 60\u2005min 8.15 \u00b1 0.90\u2005mm, P = 0.918). Meningeal artery circumference showed no significant change (baseline 4.30 \u00b1 0.83\u2005mm; 30\u2005min 4.47 \u00b1 0.68\u2005mm, P = 0.084; 60\u2005min 4.35 \u00b1 0.78\u2005mm, P = 0.688). Rimegepant did not induce measurable constriction of cerebral or meningeal arteries during spontaneous migraine attacks. These findings support its vascular safety and indicate that effective migraine relief with calcitonin gene-related peptide receptor antagonists does not depend on vasoconstriction, in contrast to triptan therapy.<\/jats:p>","DOI":"10.1093\/braincomms\/fcag004","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:44:21Z","timestamp":1767876261000},"source":"Crossref","is-referenced-by-count":5,"title":["Investigation of the rimegepant effect on cerebral and extracerebral arteries during migraine attacks: a longitudinal magnetic resonance angiography study"],"prefix":"10.1093","volume":"8","author":[{"given":"Basit Ali","family":"Chaudhry","sequence":"first","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Copenhagen University Hospital\u2014Rigshospitalet , Glostrup, DK- 2600 Glostrup ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, DK- 2200 Glostrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaira","family":"Younis","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Copenhagen University Hospital\u2014Rigshospitalet , Glostrup, DK- 2600 Glostrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Al-Mashat","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Copenhagen University Hospital\u2014Rigshospitalet , Glostrup, DK- 2600 Glostrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Gozalov","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Copenhagen University Hospital\u2014Rigshospitalet , Glostrup, DK- 2600 Glostrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq Mohammad","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Copenhagen University Hospital\u2014Rigshospitalet , Glostrup, DK- 2600 Glostrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J H","family":"de Koning","sequence":"additional","affiliation":[{"name":"Division of Image Processing, Department of Radiology, Leiden University Medical Center , Leiden, 2300 RC Leiden ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Bo Wiberg","family":"Larsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, DK- 2200 Glostrup ,","place":["Denmark"]},{"name":"Functional Imaging Unit, Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet-Glostrup , Glostrup, DK- 2600 Glostrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Copenhagen University Hospital\u2014Rigshospitalet , Glostrup, DK- 2600 Glostrup ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, DK- 2200 Glostrup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"10283","key":"2026012102521213500_fcag004-B1","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","article-title":"Migraine: Epidemiology and systems of care","volume":"397","author":"Ashina","year":"2021","journal-title":"The Lancet"},{"issue":"2","key":"2026012102521213500_fcag004-B2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","article-title":"Global epidemiology of migraine and its implications for public health and health policy","volume":"19","author":"Steiner","year":"2023","journal-title":"Nat Rev Neurol"},{"issue":"19","key":"2026012102521213500_fcag004-B3","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMra1915327","article-title":"Migraine","volume":"383","author":"Ashina","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2026012102521213500_fcag004-B4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/13696998.2025.2477342","article-title":"Lost earnings among triptan non-responders in the general population of Denmark: A measure of disproportionate migraine-attributed burden and of unrecognised and unmet treatment need","volume":"28","author":"Ashina","year":"2025","journal-title":"J Med Econ"},{"issue":"10283","key":"2026012102521213500_fcag004-B5","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","article-title":"Migraine: Disease characterisation, biomarkers, and precision medicine","volume":"397","author":"Ashina","year":"2021","journal-title":"The Lancet"},{"issue":"10268","key":"2026012102521213500_fcag004-B6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: A phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"The Lancet"},{"issue":"2","key":"2026012102521213500_fcag004-B7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene\u2013related peptide receptor antagonist, for migraine","volume":"381","author":"Lipton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10200","key":"2026012102521213500_fcag004-B8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"The Lancet"},{"issue":"3","key":"2026012102521213500_fcag004-B9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/WCO.0000000000000806","article-title":"Gepants, calcitonin-gene-related peptide receptor antagonists: What could be their role in migraine treatment?","volume":"33","author":"Moreno-Ajona","year":"2020","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"2026012102521213500_fcag004-B10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0333102419884943","article-title":"Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries","volume":"40","author":"Rubio-Beltran","year":"2020","journal-title":"Cephalalgia"},{"key":"2026012102521213500_fcag004-B11","doi-asserted-by":"crossref","first-page":"1040951","DOI":"10.3389\/fphar.2022.1040951","article-title":"Gel-forming antagonist provides a lasting effect on CGRP-induced vasodilation","volume":"13","author":"Chang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"2026012102521213500_fcag004-B12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.25831","article-title":"Anti-migraine calcitonin gene\u2013related peptide receptor antagonists worsen cerebral ischemic outcome in mice","volume":"88","author":"Mulder","year":"2020","journal-title":"Ann Neurol"},{"issue":"12","key":"2026012102521213500_fcag004-B13","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1177\/0333102413483374","article-title":"The effect of sumatriptan on cephalic arteries: A 3T MR-angiography study in healthy volunteers","volume":"33","author":"Amin","year":"2013","journal-title":"Cephalalgia"},{"issue":"5","key":"2026012102521213500_fcag004-B14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1474-4422(13)70067-X","article-title":"Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: A cross-sectional study","volume":"12","author":"Amin","year":"2013","journal-title":"Lancet Neurol"},{"issue":"4","key":"2026012102521213500_fcag004-B15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ana.22292","article-title":"Evidence for a vascular factor in migraine","volume":"69","author":"Asghar","year":"2011","journal-title":"Ann Neurol"},{"issue":"1","key":"2026012102521213500_fcag004-B16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/brain\/awy300","article-title":"Meningeal contribution to migraine pain: A magnetic resonance angiography study","volume":"142","author":"Khan","year":"2019","journal-title":"Brain"},{"issue":"10","key":"2026012102521213500_fcag004-B17","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1177\/0333102410375512","article-title":"Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan\u2014A randomised proof-of-concept trial","volume":"30","author":"Ferrari","year":"2010","journal-title":"Cephalalgia"},{"issue":"1","key":"2026012102521213500_fcag004-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"1","key":"2026012102521213500_fcag004-B19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2024.21972","article-title":"World medical association declaration of Helsinki: Ethical principles for medical research involving human participants","volume":"333","author":"World Medical Association","year":"2025","journal-title":"JAMA"},{"issue":"6","key":"2026012102521213500_fcag004-B20","doi-asserted-by":"crossref","first-page":"3331024231179131","DOI":"10.1177\/03331024231179131","article-title":"A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants","volume":"43","author":"Bertz","year":"2023","journal-title":"Cephalalgia"},{"issue":"1","key":"2026012102521213500_fcag004-B21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1129-2377-15-25","article-title":"Measurement precision and biological variation of cranial arteries using automated analysis of 3 T magnetic resonance angiography","volume":"15","author":"Amin","year":"2014","journal-title":"J Headache Pain"},{"issue":"3","key":"2026012102521213500_fcag004-B22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/brain\/awt369","article-title":"Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38","volume":"137","author":"Amin","year":"2014","journal-title":"Brain"},{"issue":"8","key":"2026012102521213500_fcag004-B23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","article-title":"Migraine and the trigeminovascular system\u201440 years and counting","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"2026012102521213500_fcag004-B24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/0333102420956692","article-title":"Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura","volume":"41","author":"Altamura","year":"2021","journal-title":"Cephalalgia"},{"issue":"10","key":"2026012102521213500_fcag004-B25","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/ph15101189","article-title":"Calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine pathogenesis","volume":"15","author":"Christensen","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"8","key":"2026012102521213500_fcag004-B26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/ph16081075","article-title":"Blocking the CGRP receptor: Differences across human vascular beds","volume":"16","author":"de Vries","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"5","key":"2026012102521213500_fcag004-B27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/0333102420983282","article-title":"Migraine therapeutics differentially modulate the CGRP pathway","volume":"41","author":"Bhakta","year":"2021","journal-title":"Cephalalgia"},{"issue":"23","key":"2026012102521213500_fcag004-B28","doi-asserted-by":"crossref","first-page":"10644","DOI":"10.1021\/jm3013147","article-title":"Discovery of (5S,6S,9R)-5-aqmino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro- 5H-cyclohepta[b]pyridin-9-yl4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxylate (BMS-927711): An oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine","volume":"55","author":"Luo","year":"2012","journal-title":"J Med Chem"},{"issue":"2","key":"2026012102521213500_fcag004-B29","doi-asserted-by":"crossref","first-page":"3331024221143773","DOI":"10.1177\/03331024221143773","article-title":"Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies","volume":"43","author":"de Boer","year":"2023","journal-title":"Cephalalgia"},{"issue":"10","key":"2026012102521213500_fcag004-B30","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1111\/head.13959","article-title":"Risk of acute myocardial infarction, heart failure, and death in migraine patients treated with triptans","volume":"60","author":"Ghanshani","year":"2020","journal-title":"Headache"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcag004\/66336475\/fcag004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/1\/fcag004\/66336475\/fcag004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/1\/fcag004\/66336475\/fcag004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:52:24Z","timestamp":1768981944000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcag004\/8419284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcag004","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcag004"}}